It has been suggested that Apo B is a more reliable indicator of Cardiovascular disease (CVD) than LDL-C, since measurement of Apo B is a direct quantitation rather than a calculated measurement. Apo Bassay is also not affected by hypertriglyceridemia as is the case with the calculated LDL-C. While LDL-C continues to constitute the primary target of therapy, the Canadian Cardiovascular Society (CCS) 2009 guideline has identified Apo B as an alternate primary target of hyperlipidemia therapy.
Apo A1 is the protein component of HDL-C and its concentration is inversely related to risk of CVD. The CCS 2009 guideline includes target values for the ratio of Apo B/Apo A.
Use of Test: Assessment of Cardiovascular Disease Risk.
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae
Read more
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae